share_log

Biora Therapeutics | DEF 14A: Definitive information statements

Biora Therapeutics | DEF 14A: Definitive information statements

Biora Therapeutics | DEF 14A：股東委託書決議
美股sec公告 ·  04/24 16:06
Moomoo AI 已提取核心訊息
Biora Therapeutics, Inc. (Biora Therapeutics) has announced its 2024 Annual Meeting of Stockholders to be held virtually on June 5, 2024. The meeting will address several key proposals, including the election of six director nominees to serve until the 2025 Annual Meeting, the ratification of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2024, and an amendment to increase the number of authorized shares of common stock from 164,000,000 to 300,000,000. Additionally, the meeting will authorize the issuance of shares of common stock underlying certain warrants issued pursuant to a Securities Purchase Agreement dated March 31, 2024, and Warrant Amendment Agreements of the same date, in compliance with Nasdaq Listing Rule 5635(d). The Board of Directors has fixed April 16, 2024, as the record date, and only stockholders of record at the close of business on that date are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. The meeting will be conducted exclusively online via live audio webcast.
Biora Therapeutics, Inc. (Biora Therapeutics) has announced its 2024 Annual Meeting of Stockholders to be held virtually on June 5, 2024. The meeting will address several key proposals, including the election of six director nominees to serve until the 2025 Annual Meeting, the ratification of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2024, and an amendment to increase the number of authorized shares of common stock from 164,000,000 to 300,000,000. Additionally, the meeting will authorize the issuance of shares of common stock underlying certain warrants issued pursuant to a Securities Purchase Agreement dated March 31, 2024, and Warrant Amendment Agreements of the same date, in compliance with Nasdaq Listing Rule 5635(d). The Board of Directors has fixed April 16, 2024, as the record date, and only stockholders of record at the close of business on that date are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. The meeting will be conducted exclusively online via live audio webcast.
Biora Therapeutics, Inc.（Biora Therapeutics）宣佈其2024年年度股東大會將於2024年6月5日虛擬舉行。會議將討論幾項關鍵提案，包括選舉六名董事候選人，任期至2025年年會，批准畢馬威會計師事務所爲截至2024年12月31日的財政年度的獨立核數師，以及將普通股授權數量從1.64億股增加到3億股的修正案。此外，會議將根據《納斯達克上市規則》第5635（d）條，授權發行根據2024年3月31日的證券購買協議和同日的認股權證修正協議發行的某些認股權證基礎的普通股。董事會已將2024年4月16日定爲記錄日期，只有在該日營業結束時的登記在冊的股東才有權獲得年度會議或其任何休會或延期的通知並在會上投票。會議將僅通過網絡直播在線進行。
Biora Therapeutics, Inc.（Biora Therapeutics）宣佈其2024年年度股東大會將於2024年6月5日虛擬舉行。會議將討論幾項關鍵提案，包括選舉六名董事候選人，任期至2025年年會，批准畢馬威會計師事務所爲截至2024年12月31日的財政年度的獨立核數師，以及將普通股授權數量從1.64億股增加到3億股的修正案。此外，會議將根據《納斯達克上市規則》第5635（d）條，授權發行根據2024年3月31日的證券購買協議和同日的認股權證修正協議發行的某些認股權證基礎的普通股。董事會已將2024年4月16日定爲記錄日期，只有在該日營業結束時的登記在冊的股東才有權獲得年度會議或其任何休會或延期的通知並在會上投票。會議將僅通過網絡直播在線進行。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息